Is There a Wegovy Pill in the UK? What Women Should Know

For many women, GLP-1 medications have become closely associated with weekly injections. But that may soon begin to change.

A tablet version of semaglutide, the active ingredient used in Wegovy, has now been approved for weight management in the UK, and it is already generating significant interest across the obesity and metabolic health space.

While injectable GLP-1 medications remain the current standard, oral GLP-1 treatments will represent the next major step in widening access and offering more choice for patients.

Here is what we know so far about the new Wegovy pill, what makes it different, and what it could mean for the future of weight management.

Is there a Wegovy pill available in the UK?

Yes! The MHRA approved the Wegovy pill on the 11th July 2026. What people call the "Wegovy pill" is an oral version of semaglutide.

What is the Wegovy pill?

The Wegovy pill is an oral version of semaglutide, a GLP-1 medication already used in injectable treatments such as Wegovy and Ozempic.

Semaglutide works by mimicking a natural hormone in the body called GLP-1, which helps regulate appetite, hunger signals, blood sugar levels, feelings of fullness, and food cravings.

The tablet aims to deliver similar metabolic and appetite-regulating effects as injectable semaglutide, but in a once-daily pill format rather than a weekly injection.

Is this a completely new medication?

Not entirely.

An oral form of semaglutide already exists for type 2 diabetes under the name Rybelsus. However, the higher-dose oral semaglutide being studied for weight management is designed specifically for obesity and weight-related health conditions, and requires its own separate MHRA review and approval.

How is a semaglutide pill absorbed differently from an injection?

Unlike injectable semaglutide, oral semaglutide needs to be absorbed through the stomach. Because of this, the tablet usually has stricter instructions around how it is taken.

Current oral semaglutide tablets are typically taken first thing in the morning, on an empty stomach, with a small amount of water, followed by a waiting period before eating or drinking. This routine may not suit everyone, which is why injections may still be preferable for some women despite the convenience of a pill.

Is oral semaglutide approved anywhere else in the world?

Yes. The FDA in the United States has also approved a higher-dose oral semaglutide specifically for chronic weight management.

What would the Wegovy pill mean for women?

Why are so many women interested in an oral option? For many, the biggest barrier to starting a GLP-1 medication is the idea of injections. While most people adapt quickly to weekly injections, others dislike needles, worry about self-injecting, travel frequently, prefer tablets over injectable medications, or simply want more treatment choice.

An oral option could make GLP-1 treatment feel more accessible and convenient for some women. But convenience is only part of the story.

The growing interest in oral GLP-1 medications also reflects a wider shift in how obesity and metabolic health are being understood. Increasingly, obesity is being recognised as a complex biological and metabolic condition, not simply a matter of willpower.

Could the Wegovy pill benefit women with PMOS?

Polyendocrine Metabolic Ovarian Syndrome (PMOS) affects roughly one in ten women of reproductive age in the UK and is closely linked to insulin resistance, difficulty managing weight, and an elevated risk of type 2 diabetes. GLP-1 receptor agonists like semaglutide have shown promising results in women with PCOS, supporting weight loss and potentially improving hormonal and metabolic markers alongside it.

For women with PMOS who have avoided injectable treatments due to needle anxiety, an oral form of semaglutide could offer a more accessible route into this class of medication. This remains an area of active clinical interest.

Please note, Polycystic Ovarian Syndrome was recently renamed Polyendocrine Metabolic Ovarian Syndrome. You can read our latest PMOS article on the name change and why this occured.

The Wegovy pill and menopause-related weight gain

Weight gain during perimenopause and menopause is extremely common and often resistant to the dietary and lifestyle approaches that worked earlier in life. GLP-1 medications have emerged as a clinically meaningful option for women navigating menopausal weight changes, because they address the appetite and metabolic pathways that shifting hormones disrupt.

An oral option would be particularly welcome in this group, many women in their 40s and 50s are already managing multiple daily medications and would find a tablet significantly easier than a self-administered injection. With oral semaglutide receiving UK approval, it will now to be one of the most discussed treatment options for weight management in this life stage.

Wegovy pill vs Wegovy injection: which is right for you?

Will the pill replace injections? Probably not.

Injectable GLP-1 medications are still expected to remain an important treatment option, and for some women they may continue to offer stronger or more consistent effects. Instead, oral semaglutide is more likely to increase treatment choice.

Some women may prefer injections because they are weekly rather than daily, because they fit more easily into routine, or because of how their body responds to treatment. Others may feel more comfortable starting with a tablet.

The future of obesity treatment will likely involve more personalised approaches, where treatment decisions are based on lifestyle, medical history, goals, preferences, side effect profile, and metabolic health needs. Our full guide on pills vs injections dives in further to the topic.

How to take the Wegovy pill: dosing and daily routine

Unlike the injection, which is taken once a week, the Wegovy pill requires a consistent daily routine to work effectively. Because oral semaglutide is absorbed through the stomach lining rather than injected directly into the bloodstream, how you take it matters as much as whether you take it.

The pill must be taken first thing in the morning on an empty stomach, with a small sip of plain still water only. Food, drink, and other medications should be avoided for at least 30 minutes afterwards. Skipping this window does not just reduce comfort, it can significantly reduce how much semaglutide your body actually absorbs.

The dose escalates gradually from 1.5mg up to a maximum of 25mg, with at least one month at each level to allow your body to adjust.

For a full breakdown of the dosing schedule, what to do if you miss a dose, and practical tips for building the routine into your morning, read our complete guide: How to take the Wegovy pill.

Wegovy pill side effects: what women should know

The side effects are expected to be similar to injectable GLP-1 medications because the active ingredient is still semaglutide. Common side effects may include nausea, constipation, diarrhoea, bloating, reduced appetite, and fatigue. As with injectable treatments, side effects often improve gradually over time, particularly with slower dose increases and appropriate clinical support. For a full breakdown of what to expect, read our complete guide to Wegovy pill side effects.

Side effects of the Wegovy pill specific to women

Some evidence suggests women may be more susceptible to nausea-related side effects with GLP-1 medications, as female sex and a history of motion sickness are recognised predictors of nausea sensitivity in broader clinical research. GLP-1 medications can also slow gastric emptying, which may contribute to gastrointestinal symptoms such as nausea, bloating and vomiting. Individual tolerance can additionally be influenced by hormonal factors and differences in gut motility and the brain–gut axis. This is why personalised clinical oversight and gradual dose escalation can be important in supporting women to tolerate treatment successfully.

Oral semaglutide is not recommended during pregnancy or breastfeeding. Women with a personal or family history of thyroid conditions, pancreatitis, or eating disorders should discuss their suitability carefully with a clinician before starting.

What weight loss options are available to women in the UK right now?

At SheMed, we know that no single treatment approach works for everyone. We have a range of options available both in pill and injection format.

Wegovy injection: what it is and how it works

The Wegovy injection (semaglutide 2.4mg, once weekly) is licensed in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related health condition. Clinical trials have demonstrated average weight loss of up to 28% of body weight. For women who want the clinical benefits of semaglutide now, the injection is the licensed, proven route.

‍

Frequently asked questions about the Wegovy pill in the UK

Can I buy the Wegovy pill online in the UK?

Yes. It's now approved and ready to purchase in the UK after the MHRA gave it the green light on July 11th 2026. It's now available from SheMed from just £69 per month. Read more on the Wegovy pill costs.

Is the Wegovy pill the same as Rybelsus?

Not exactly. Both contain oral semaglutide, but they are different products. Rybelsus is a lower-dose oral semaglutide licensed in the UK for type 2 diabetes, not weight loss.

Is oral semaglutide safe for women?

Clinical trial data has shown a safety profile broadly consistent with injectable semaglutide, with large numbers of female participants included in trials. Common side effects include nausea and gastrointestinal discomfort, particularly at the start of treatment. Oral semaglutide is not recommended during pregnancy or breastfeeding, and women with certain thyroid conditions, pancreatitis, or a history of eating disorders should seek careful clinical assessment before starting.

What is the difference between Wegovy and oral semaglutide?

Wegovy is the brand name for the injectable form of semaglutide (with dosing up to 7.2mg, once weekly) licensed for weight loss in the UK. Oral semaglutide is a tablet form of the same drug. Both work through the same GLP-1 mechanism but differ in how they are taken, how the drug is absorbed, and the dosing routine required.

Will the NHS prescribe the Wegovy pill when it's approved?

This will depend on NICE guidance, which follows MHRA licensing. The Wegovy injection received a restricted NICE recommendation in 2023, limiting NHS prescribing to specialist weight management services. Oral semaglutide is likely to follow a similar pathway meaning NHS access may initially be limited, while private prescribing could become available more broadly.

Who is eligible for the Wegovy pill in the UK?

The Wegovy pill is a prescription-only medication and requires a clinical assessment before it can be prescribed. Eligibility criteria for private prescribing in the UK are broadly the same as for the injectable Wegovy:

You may be eligible if you have a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea.

Meeting the BMI threshold alone does not automatically mean the pill is suitable for you. Your prescriber will also review your full medical history, any current medications, and whether there are any contraindications. The Wegovy pill is not recommended for women who are pregnant or breastfeeding, or those with a personal or family history of medullary thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome type 2.

NHS access to the Wegovy pill will follow a separate pathway. As with the injectable Wegovy, this will require a NICE appraisal before NHS prescribing can begin, and initial access is likely to be restricted to specialist weight management services. Private prescribing is available now.

If you would like to find out whether you are eligible, you can start with a SheMed health check.

‍

What does this mean for you?

At SheMed, we know that no single treatment approach works for everyone. The potential arrival of oral GLP-1 medications reflects something important: weight management treatment is continuing to evolve, becoming more personalised, more accessible, and more focused on long-term metabolic health.

As always, our focus remains on supporting women with evidence-based care, clinical oversight, personalised treatment, lifestyle support, and sustainable long-term health outcomes.

We will continue monitoring updates around oral semaglutide and will keep you informed as more information becomes available. In the meantime, if you would like to explore your current options with a clinician who understands women's health, start with a health check.

‍

References

1. Medicines and Healthcare products Regulatory Agency (MHRA). First GLP-1 tablet for weight loss approved in the UK. GOV.UK. 11 June 2026.
2. Wharton S, et al.; OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2024;393(11).
3. Wilding JPH, Batterham RL, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
4. National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity (TA875). Published 8 March 2023, updated September 2023.
5. US Food and Drug Administration. FDA approves oral semaglutide as first GLP-1 pill for weight loss. December 2025.
6. Medicines and Healthcare products Regulatory Agency. Rybelsus (semaglutide tablets): transition to new formulation. Drug Safety Update. December 2025.
7. The Pharmaceutical Journal. MHRA approves semaglutide oral tablets for weight loss. 11 June 2026.

‍